The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

##STR00001##

The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging; wherein the inhibitors of NLRP3 inflammasomes are compounds of Formula VII: ##STR00001##
or a pharmaceutically acceptable salt thereof.

The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging; wherein the inhibitors of NLRP3 inflammasomes are compounds of Formula VII: ##STR00001##
or a pharmaceutically acceptable salt thereof.

A borate compound-containing composition soluble in hydrocarbon solvents. A composition containing base A, or a compound having a total carbon number of not less than 8 and represented by the formula (5):

##STR00001##

wherein R and R′ are each independently an optionally substituted C.sub.1-30 alkyl group, an optionally substituted C.sub.3-15 cycloalkyl group, or an optionally substituted C.sub.6-14 aryl group; and
a borate compound represented by the following formula (1):

##STR00002##

wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each independently a C.sub.6-14 aryl group substituted by one or more fluorine atoms or fluoro C.sub.1-4 alkyl groups; and
[A-H].sup.+ is a base A-derived cation. A method for producing a polymer, by polymerizing at least one kind of monomer selected from the group consisting of olefins and dienes by using the composition A as a cocatalyst.

The invention relates to a compound of formula (I) wherein R.sup.1-R.sup.3 are as defined in the description and in the claims The compound of formula (I) can be used as a medicament.

##STR00001##

The invention relates to a compound of formula (I) wherein R.sup.1-R.sup.3 are as defined in the description and in the claims The compound of formula (I) can be used as a medicament.

##STR00001##

The present disclosure relates to compounds of Formula I: ##STR00001##
that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.

The present disclosure relates to compounds of Formula I: ##STR00001##
that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.

The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.

The present invention relates to a pidolate salt and malate salt of a compound represented by a formula 1 with an excellent liquid-phase stability, solid-phase stability, water solubility, precipitation stability and hygroscopicity all together as a compound for preventing and treating diseases mediated by an acid pump antagonistic activity, as well as a method for preparing the same.